ClinicalIntelPulse

Live 402 challenge

Captured by the enrichment pass, not read just now. Prices can change — always read the 402 the endpoint answers with.

{
  "error": "X-PAYMENT header is required",
  "accepts": [
    {
      "asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
      "extra": {
        "name": "USD Coin",
        "version": "2"
      },
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "scheme": "exact",
      "network": "base",
      "mimeType": "application/json",
      "resource": "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/global-trials",
      "description": "Global clinical trial landscape for any disease — geographic distribution by country across WHO ICTRP registries (US, EU, China, India, Japan, Brazil, Africa and more), regulatory pathways, access gaps and unmet need by region. For CRO, global-pharma and advocacy agents.",
      "maxAmountRequired": "150000",
      "maxTimeoutSeconds": 300
    }
  ],
  "x402Version": 1
}

Accepts

The payment requirements as published to the catalog. Read the live 402 before paying — a price here is a claim, not a quote.

[
  {
    "asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
    "extra": {
      "name": "USD Coin",
      "version": "2"
    },
    "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
    "amount": "150000",
    "scheme": "exact",
    "network": "eip155:8453",
    "maxTimeoutSeconds": 300
  },
  {
    "asset": "EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v",
    "extra": {
      "feePayer": "BFK9TLC3edb13K6v4YyH3DwPb5DSUpkWvb7XnqCL9b4F"
    },
    "payTo": "985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1",
    "amount": "150000",
    "scheme": "exact",
    "network": "solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp",
    "maxTimeoutSeconds": 300
  }
]

Extensions

{
  "bazaar": {
    "info": {
      "input": {
        "type": "http",
        "method": "GET",
        "queryParams": {
          "lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)",
          "region": "global | africa | asia | europe | latin-america | middle-east | north-america (default: global)",
          "condition": "Disease — e.g. \"Malaria\" | \"Tuberculosis\" | \"Dengue\" | \"Sickle Cell Disease\" | \"Chagas Disease\""
        }
      },
      "output": {
        "type": "json",
        "example": {
          "query_summary": {
            "region": "global",
            "condition": "Malaria"
          },
          "phase3_highlights": [
            {
              "drug": "R21/Matrix-M",
              "notes": "WHO prequalification received 2023. First malaria vaccine with >75% efficacy in high-transmission settings.",
              "sponsor": "Serum Institute / Oxford",
              "countries": [
                "Burkina Faso",
                "Kenya",
                "Mali",
                "Tanzania"
              ]
            }
          ],
          "regulatory_landscape": {
            "ema": "Article 58 mechanism for non-EU disease burden assessments. R21 assessed via UK MHRA.",
            "fda": "Limited footprint — malaria not a US priority market; few NDA filings",
            "nmpa_china": "Artemisinin derivatives approved; combination therapies standardized under WHO guidelines",
            "who_prequalification": "Primary pathway for SSA deployment. RTS,S and R21 both WHO-prequalified."
          },
          "unmet_needs_by_region": {
            "latin_america": "Vivax malaria (neglected vs. falciparum)",
            "southeast_asia": "Artemisinin resistance (Pfkrelch mutations) — urgent — treatment of resistant falciparum",
            "sub_saharan_africa": "Pediatric dosing, pregnancy, severe malaria, transmission blocking"
          },
          "opportunity_assessment": "R21 scale-up is the near-term priority. Resistance crisis in SE Asia creates urgent Phase 3 need for alternative regimens.",
          "global_trial_distribution": {
            "most_active_countries": [
              "Kenya (45 trials)",
              "Uganda (38)",
              "Burkina Faso (31)",
              "Mali (28)",
              "Tanzania (24)",
              "United States (22)",
              "Thailand (19)"
            ],
            "clinicaltrials_gov_count": 312,
            "geographic_concentration": "Sub-Saharan Africa dominates — 68% of all active malaria trials",
            "estimated_non_us_registries": "200+ additional trials in WHO ICTRP member registries"
          },
          "global_registries_coverage": {
            "ctri_india": "18 trials — India significant manufacturer (Serum Institute)",
            "chictr_china": "Limited malaria — primarily domestic infectious disease",
            "anzctr_australia": "5 trials — malaria research centers in Melbourne (Burnet Institute)",
            "clinical_trials_eu": "12 EU-registered trials"
          },
          "development_finance_context": "GAVI, Global Fund, UNITAID, PMI, USAID funding dominant. Wellcome Trust largest private funder."
        }
      }
    },
    "schema": {
      "type": "object",
      "$schema": "https://json-schema.org/draft/2020-12/schema"
    }
  },
  "builder-code": {
    "info": {
      "a": "bc_gxy6qn5p"
    },
    "schema": {
      "type": "object",
      "$schema": "https://json-schema.org/draft/2020-12/schema",
      "properties": {
        "a": {
          "type": "string",
          "pattern": "^[a-z0-9_]{1,32}$",
          "description": "App builder code"
        },
        "s": {
          "type": "array",
          "items": {
            "type": "string",
            "pattern": "^[a-z0-9_]{1,32}$"
          },
          "description": "Service builder codes"
        },
        "w": {
          "type": "string",
          "pattern": "^[a-z0-9_]{1,32}$",
          "description": "Wallet builder code"
        }
      },
      "additionalProperties": false
    }
  }
}

Provenance

Seen in the source catalog

2026-07-01 04:24Z

Last indexed by Roundhouse

2026-07-30 16:00Z

Last enriched (probe, favicon, geo)

2026-09-11 09:45Z

x402 version

2

Max timeout

300s

Liveness probe

HTTP 402